Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • IQVIA AI Assistant
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Meet the IQVIA AI Assistant

Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
15+ Years of Biosimilar Experience in Europe
Omnitrope® case study
Nov 24, 2022
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Report Summary

Biosimilar competition can play a crucial role in the overall economic sustainability of the healthcare system. Biosimilars hold the potential to improve patient access to biologic therapies, balance spending, and unlock savings for innovation. IQVIA Institute has previously published reports on biosimilar sustainability (Advancing Biosimilar Sustainability, 2018, and Spotlight on Biosimilars, 2021).

This new report continues the conversation by assessing the status of biosimilar use in selected European countries and, in particular, by analyzing the value provided by the first biosimilar launched in Europe — Omnitrope®. This utilization of Omnitrope and the savings associated with it are assessed using proprietary IQVIA data for selected European countries. With more than 15 years since its approval, Omnitrope’s value to the overall health system is important to understand and can provide lessons for ensuring that future biosimilars are optimally utilized.

Key Findings

  • Over the past 15+ years, several studies have been conducted that show Omnitrope® to be highly similar to Genotropin, the reference product in pharmacokinetic and pharmacodynamic safety and efficacy profiles, and comparable in quality, safety, and efficacy.
  • In these 15+ years, Omnitrope has also witnessed access and uptake in most European countries and has a 30% share of overall somatropin usage; however, its uptake trajectory differs from that of more recent biosimilar products.
  • Based on analysis of IQVIA MIDAS data, the entry of Omnitrope (somatropin) has led to more than $1.9 billion in savings at a list price level across selected European countries between 2006 and 2021, driven by its reduced cost and the increased competitive pressure on reference medicines.
  • The level of savings varies across countries, considering biosimilar uptake, competitive response and regulations are different.

Other Findings

  • There has been a gradual increase in the Omnitrope share of the somatropin market in terms of volume as more countries have provided access to the biosimilar and there has been greater acceptance of it across all countries; the percentage share increased from 13% in 2012 to 30% in 2022.
  • Overall, there has been an increase of 101% in annual somatropin volume use since 2006 while the overall sales have only increased by 34%.
  • Across the countries, Omnitrope has had greater than 300,000 patient years of usage over the 15 years, with the highest use taking place in France, Spain, Germany, and Poland.
  • The total cumulative savings associated with Omnitrope across all countries since 2006 is estimated to be $1.9 billion at a list price level (approximately 14% of the overall somatropin spending in the same period) with the highest savings taking place in France, Spain, the UK, and Italy.

You may also be interested in

Case Study
Unlocking Market Expansion with Precise Disease-Segmented Strategies
Case Study
Unlocking Market Expansion with Precise Disease-Segmented Strategies
Article
Addressing Biosimilar Clinical Trial Challenges with the IQVIA Biosimilar Site Network
Article
Orphan Drug Exclusivity: A Lifeline for Rare Disease Patients
Institute Report
Long-term Market Sustainability for Infused Biosimilars in the U.S.
White Paper
China: An Early Opportunity for Emerging Biopharma
Prev
Next

Related solutions

Biosimilars

Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us